RxGen, Inc. Awarded Phase I Of Fast Track SBIR For Study Of Environmental Causes Of Parkinson's Disease 
10/19/2005 5:12:23 PM

RxGen, Inc. (, a private biotechnology company, announced today that the National Institutes of Health (NIH) has funded Phase I of the company's Fast Track SBIR grant for $1.1 million to uncover genomic markers of Parkinson's disease. RxGen is leveraging the latest genomics and bioinformatics technologies and its unique knowledge of primate models of Parkinson's disease to profile in vivo brain RNA expression patterns following exposure to compounds known to cause the neuronal injury and dopamine depletion associated with Parkinson's disease.